Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Non-Current Assets (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Non-Current Assets readings, the most recent being $5.7 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 28.69% to $5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $26.3 million, a 26.32% decrease, with the full-year FY2025 number at $5.7 million, down 28.69% from a year prior.
  • Non-Current Assets hit $5.7 million in Q4 2025 for Aligos Therapeutics, down from $6.3 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $30.9 million in Q4 2021 to a low of $5.7 million in Q4 2025.
  • Median Non-Current Assets over the past 5 years was $11.5 million (2023), compared with a mean of $12.0 million.
  • Biggest five-year swings in Non-Current Assets: surged 102.45% in 2021 and later plummeted 57.51% in 2022.
  • Aligos Therapeutics' Non-Current Assets stood at $30.9 million in 2021, then plummeted by 57.51% to $13.1 million in 2022, then decreased by 20.57% to $10.4 million in 2023, then fell by 23.84% to $8.0 million in 2024, then dropped by 28.69% to $5.7 million in 2025.
  • The last three reported values for Non-Current Assets were $5.7 million (Q4 2025), $6.3 million (Q3 2025), and $6.8 million (Q2 2025) per Business Quant data.